Adrenal Cortical CarcinomaCCSTRNCT07335679
Characterization of the Strasbourg Cohort of Patients With Adrenal Cortex Carcinoma
An observational study of Adrenal Cortical Carcinoma, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
Adrenal corticosteroid carcinoma (ACC) is a rare tumor of the adrenal cortex, with an estimated prevalence of 0.5 to 2 cases per million inhabitants per year. Two peaks in incidence have been described: during the first decade of life and between 40 and 50 years of age, with a slight female predominance… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Adrenal Cortical Carcinoma
- How many people
- 60 participants
- Where
- 1 siteFrance
- Study dates
- 10 Jun 2025to 10 Jun 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: - Adult subject (≥ 18 years old) followed at Strasbourg University Hospital for adrenal cortical carcinoma diagnosed between January 1, 2000, and May 31, 2025
Who may be able to join
- Adult subject (≥ 18 years old)
- Subjects followed at Strasbourg University Hospital for adrenal cortical carcinoma diagnosed between January 1, 2000, and May 31, 2025
Who cannot join
- Tumor reclassified as non-SCC by histopathology
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service d'Endocrinologie, Diabétologie, Nutrition - CHU de Strasbourg - France
Strasbourg, 67091
Philippe BALTZINGER, MD, 33 3 88 12 75 82, philippe.baltzinger@chru-strasbourg.fr
Philippe BALTZINGER, MD
About this study
Adrenal corticosteroid carcinoma (ACC) is a rare tumor of the adrenal cortex, with an estimated prevalence of 0.5 to 2 cases per million inhabitants per year.
Two peaks in incidence have been described: during the first decade of life and between 40 and 50 years of age, with a slight female predominance (female-to-male ratio of 1.5). The majority of cases (>90%) are sporadic, particularly in adults.
Read more
ACC may be discovered incidentally during an imaging examination performed for another reason (10 to 20% of cases) or in connection with a tumor syndrome (40-60% of cases) or hormonal hypersecretion (40 to 74% of cases). The diagnosis of CCS can be suggested by the combination of morphological characteristics seen on imaging and clinical and biological features (secretory syndrome), but only histopathology allows for a definitive diagnosis. Furthermore, histopathology enables the assessment of aggressiveness criteria (Weiss score, Ki67), which will influence further management and prognosis.
Given that CCS is a rare tumor, the investigators aim to study the clinical, biological, morphological, and histological characteristics and evaluate the prognosis of patients treated at our center in order to better understand the natural history of CCS and improve patient management.
- Conditions
- Adrenal Cortical Carcinoma
- Keywords
- Adrenal cortical carcinoma
- Medical subject headings
- Adrenocortical Carcinoma
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall, specific, and progression-free survival in patients treated for adrenal cortical carcinoma (ACC)
Overall survival:
Is how long patients live after being diagnosed or treated, regardless of the cause of death.
Example: If 100 patients are treated for ACC and 60 are alive after 5 years, the 5-year overall survival is 60%. It counts everyone, whether they die from ACC or something else, like an accident or another illness.
Measured: Up to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2026
- Study start10 Jun 2025
- Primary completionJun 2027 (estimated)
- Study completion10 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adrenal Cortical CarcinomaStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07335679
- Sponsor's protocol ID
- 9693
- Acronym
- CCSTR
- Status last verified
- Jan 2026
- First submitted
- 2 Jan 2026
- Last updated
- 13 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Characterization of the Strasbourg Cohort of Patients With Adrenal Cortex Carcinoma
- ClinicalTrials.gov ID
- NCT07335679
- Acronym / sponsor ID
- CCSTR / 9693
- Conditions
- Adrenal Cortical Carcinoma
- Keywords
- Adrenal cortical carcinoma
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 10 Jun 2025 (actual)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- 10 Jun 2027 (estimated)
- First posted
- 13 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Adrenal corticosteroid carcinoma (ACC) is a rare tumor of the adrenal cortex, with an estimated prevalence of 0.5 to 2 cases per million inhabitants per year.
Two peaks in incidence have been described: during the first decade of life and between 40 and 50 years of age, with a slight female predominance (female-to-male ratio of 1.5). The majority of cases (>90%) are sporadic, particularly in adults.
ACC may be discovered incidentally during an imaging examination performed for another reason (10 to 20% of cases) or in connection with a tumor syndrome (40-60% of cases) or hormonal hypersecretion (40 to 74% of cases). The diagnosis of CCS can be suggested by the combination of morphological characteristics seen on imaging and clinical and biological features (secretory syndrome), but only histopathology allows for a definitive diagnosis. Furthermore, histopathology enables the assessment of aggressiveness criteria (Weiss score, Ki67), which will influence further management and prognosis.
Given that CCS is a rare tumor, the investigators aim to study the clinical, biological, morphological, and histological characteristics and evaluate the prognosis of patients treated at our center in order to better understand the natural history of CCS and improve patient management.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- - Adult subject (≥ 18 years old) followed at Strasbourg University Hospital for adrenal cortical carcinoma diagnosed between January 1, 2000, and May 31, 2025
Key inclusion criteria (2 listed)
- Adult subject (≥ 18 years old)
- Subjects followed at Strasbourg University Hospital for adrenal cortical carcinoma diagnosed between January 1, 2000, and May 31, 2025
Key exclusion criteria (1 listed)
- Tumor reclassified as non-SCC by histopathology
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Overall, specific, and progression-free survival in patients treated for adrenal cortical carcinoma (ACC)
Time frame: Up to 12 months
Overall survival: Is how long patients live after being diagnosed or treated, regardless of the cause of death. Example: If 100 patients are treated for ACC and 60 are alive after 5 years, the 5-year overall survival is 60%. It counts everyone, whether they die from ACC or something else, like an accident or another illness.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2026.
Related trials for Adrenal Cortical Carcinoma
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruitingPhase 2
Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.
Adrenocortical Carcinoma
RecruitingPhase 1
Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma
Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC)
RecruitingPhase 2
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma
RecruitingObservational study
Adrenal Diseases in the Population of Modena: A Clinical-Epidemiological Database of Patients Referred to the Adrenal Disorders Outpatient Clinic of the Clinical Unit of Endocrinology at the Modena University Hospital (AOU Modena)
Cushing s Syndrome, Cushing Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Adrenal Cortical Carcinoma, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Philippe BALTZINGER, MD (33 3 88 12 75 82, philippe.baltzinger@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall, specific, and progression-free survival in patients treated for adrenal cortical carcinoma (ACC) (time frame: Up to 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2026.